Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  2. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  3. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  4. Drug

    Neovastat

    go.drugbank.com/drugs/DB05387
    Investigational

    It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer. … Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases

  5. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. … NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    In addition, unlike currently marketed opioids, CR665 does not produce inhibition of intestinal transit (ileus), induce respiratory depression, or elicit signs of euphoria or addiction in animal models … In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound.

  7. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

    Categories: Beta Blocking Agents, Non-Selective
  9. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. … Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  10. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.